An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Apabetalone (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Biomarker
- Sponsors Resverlogix Corporation
- 08 Feb 2018 According to a Resverlogix Corporation media release, company expects to enroll its first patient in this trial during the second quarter of 2018.
- 20 Oct 2017 Planned End Date changed from 15 Nov 2018 to 15 May 2019.
- 20 Oct 2017 Planned primary completion date changed from 30 Oct 2018 to 30 Apr 2019.